Lopecia

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lopecia

What is Lopecia? — Overview and Identity

Property Description
Active Ingredient Finasteride
Form Oral Tablet (Prescription-Only)
Pharmacological Class 5alpha-Reductase Inhibitor
General Purpose To modulate the effects of the potent androgen Dihydrotestosterone (DHT)
Origin Synthetic Azasteroid

Defining Lopecia: Core Classification and Differentiation

Lopecia is a single-ingredient, prescription-only medication whose active component is Finasteride, classifying it as a selective Type II 5alpha-Reductase Inhibitor. The drug is a synthetic 4-azasteroid compound that operates systemically following oral administration via a film-coated tablet. This chemical classification is clinically recognized for intervening in the body's androgen metabolism to achieve a therapeutic hormonal effect. While the specific brand name Lopecia positions this product in the global marketplace, its fundamental identity is derived from Finasteride.

Mechanism and Recognized Therapeutic Purpose

The medicine’s unique physiological action is the competitive inhibition of the 5alpha-reductase enzyme, which blocks the conversion of the hormone Testosterone into the more potent androgen, Dihydrotestosterone (DHT). This targeted mechanism is associated with a pronounced reduction in both plasma and tissue levels of DHT. The reduction of DHT is the singular, central action of Lopecia. Consequently, the general purpose of the drug is to counteract conditions that are driven by the high concentration or excessive activity of the DHT hormone in sensitive tissues, providing a recognized antiandrogenic effect.

Regulatory References

  1. Finasteride - StatPearls (NCBI)

What side effects are possible with Lopecia?

Possible Side Effects and Safety Information

Adverse reactions to Lopecia (finasteride) are classified by regulatory agencies based on frequency and the affected body system. All statements regarding safety and risk are derived directly from official government regulatory documents.

Classification Affected Systems and Reactions (Examples)
Common (Affects 1 to 10 users in 100) Decreased interest in sex (libido), difficulty achieving an erection, and ejaculation disorder, including decreased ejaculate volume.
Uncommon (Affects 1 to 10 users in 1,000) Rash, breast enlargement, and breast tenderness.
Frequency Not Known Depression (including depressed mood), anxiety, testicular pain, and the potential for sexual dysfunction to continue after stopping treatment.

Serious Adverse Reactions and Safety Constraints

The official labeling includes reports of rare but clinically significant adverse reactions, categorized in post-marketing experience. These include male breast cancer and reports of suicidal ideation and behavior added to product information by multiple regulatory authorities.

Population-Specific Safety Notes:

  • Pregnant Females: Lopecia is contraindicated for use in women. Women who are pregnant or may potentially be pregnant must not handle crushed or broken tablets due to the potential for absorption and risk of abnormal external genitalia development in a male fetus.
  • Pediatric Use: The medication is not indicated for use in children or adolescents.

Regulatory Safety Limitations:

Lopecia reduces serum levels of Prostate-Specific Antigen (PSA) by approximately 50%. This change must be accounted for when interpreting PSA results for prostate cancer screening, as an increase in the recorded level may signal the presence of prostate cancer, even if the value remains within the normal range for men not taking this type of medication.

Connection to the overall safety profile:

The official safety information for Lopecia structures the understanding of potential risk by clearly defining adverse reactions according to established frequency categories and affected physiological systems. This profile highlights specific safety constraints, such as the mandated caution regarding PSA interpretation and the absolute restriction on handling by pregnant women. It documents the potential for adverse effects, particularly sexual and psychiatric events, and includes reports of rare, serious outcomes documented post-marketing.

Overdose and Emergency Response

Lopecia Overdose and When to Seek Help

The official regulatory profile for Lopecia (Finasteride) overdose is established based on observations from human clinical studies. These data demonstrate that the medicine has been well-tolerated following exposure to single oral doses administered up to 400 mg, which is significantly higher than the standard therapeutic dosage. Even daily doses up to 80 mg maintained for 12 weeks did not result in the documentation of specific, severe, or acute adverse clinical manifestations. Consequently, no specific symptoms or clinical syndrome are consistently detailed in regulatory labeling as typical presentations of acute Finasteride overexposure.

Since the drug lacks a documented acute toxicity profile, no specific antidote is known or available for Finasteride overexposure. Regulatory authorities and official prescribing information universally mandate that individuals seek emergency medical treatment immediately in the event of a suspected or confirmed overdose. This required action ensures that management, which should be symptomatic and supportive, can be administered in a professional healthcare setting.

For specific patient groups, official pharmacokinetic data indicates that the drug's disposition in individuals with chronic renal impairment is comparable to that of healthy subjects. Despite this, the explicit guidance to seek emergency medical attention remains the mandatory instruction for all individuals experiencing a suspected overdose.

Therapeutic Uses of Lopecia

Lopecia (finasteride) is commonly used to help with conditions presenting with acute episodes in men, primarily addressing two distinct therapeutic areas. The medication may assist with managing the symptoms related to physical discomfort associated with an enlarged prostate (benign prostatic hyperplasia or BPH) and plays a role in managing male pattern hair loss (androgenetic alopecia). This approach is considered relevant when supportive symptom management is appropriate, particularly for conditions characterized by periods of heightened symptoms (BPH flare-ups) or symptoms associated with acute or episodic changes (hair loss progression). This provides support that helps ease the overall symptom burden in settings marked by temporary physiological imbalance. The benefit to the patient contributes to easing the overall symptom load and assists with maintaining functional stability when symptoms interfere with routine activities. For example, regarding BPH, it contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Focus on easing the overall symptom burden

Eligibility and Restrictions for Use

Official Eligibility for Lopecia (Finasteride)

Lopecia is strictly classified for use only in adult men. The official regulatory labeling defines several absolute exclusions and conditional use requirements for specific populations.

Populations Who Must Not Use Lopecia (Contraindications)

The medicine is contraindicated and must not be used by the following groups:

  • Women: The medicine is explicitly prohibited for use in all women.
  • Pregnancy and Potential Pregnancy: Lopecia is absolutely contraindicated in women who are or may potentially be pregnant due to the risk of causing abnormalities in the external genitalia of a male fetus (teratogenicity). Furthermore, women who are or may be pregnant should not handle crushed or broken tablets.
  • Pediatric Patients: Use is contraindicated in children and adolescents under 18 years of age, as safety and effectiveness have not been established in this population.
  • Hypersensitivity: Individuals with a known allergy or hypersensitivity to finasteride or any other component of the tablet.

Conditional Use and Age Rules

  • Hepatic Impairment: Caution is advised for patients with liver function abnormalities, as the active substance is extensively metabolized in the liver, and formal studies in this group are limited.
  • Renal Impairment: No dosage adjustment is necessary for patients with renal insufficiency.
  • Older Adults: No dosage adjustment is necessary for use in the elderly.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Lopecia (Finasteride)

The active ingredient of Lopecia is defined by regulatory agencies as having a profile of minimal clinically important drug-drug interactions.

Interaction scope

Category Regulatory Status
Medicinal product categories with documented interactions None are defined as having a broad category-level interaction.
Specific interacting medicines (if explicitly listed) Official studies found no clinically meaningful interactions with: Antipyrine, Digoxin, Propranolol, Theophylline, and Warfarin.
Mechanistic basis of interactions (only if stated in label) Finasteride does not appear to affect the cytochrome P450-linked drug-metabolizing enzyme system.
Timing-based interaction rules (if applicable) No mandatory timing rules are documented; the product may be taken with or without meals.
Population-specific interaction notes (if applicable) Caution is formally documented for administration in patients with liver function abnormalities (hepatic impairment) due to the drug’s extensive hepatic metabolism.
Interaction-related restrictions No drug-drug combinations are officially classified as contraindicated due to interaction risk.

Interaction classifications (high-level)

Category Official Regulatory Statement
Interaction severity classification No drug interactions of clinical importance have been identified.
Food, alcohol, herbal product interactions Food does not affect bioavailability. The herbal product St John's Wort is noted by some health authorities as potentially reducing the intended effect.

Resulting interaction structure

Official interaction statements confirm that the drug does not appear to affect the cytochrome P450-linked drug-metabolizing enzyme system. This minimal metabolic impact is supported by findings of no clinically meaningful changes in exposure when co-administered with specific compounds like Digoxin and Warfarin. The single interaction-related constraint is the requirement for caution in patients with liver function abnormalities due to the drug's primary metabolic route.

Mechanism of Action

Selective 5alpha-Reductase Type II Enzyme Inhibition

This mechanism of action is founded on the drug’s role as a highly specific competitive inhibitor of the Type II 5alpha-Reductase enzyme. By forming a stable complex with the target enzyme, Finasteride effectively inactivates its function. This mechanistic domain initiates the molecular blockade that precedes the hormonal cascade.


Modulation of the Androgen Metabolism Pathway

The core function is the systemic modulation of the androgen metabolism pathway. The enzyme deactivation prevents the conversion of Testosterone into Dihydrotestosterone (DHT). This interruption leads to a significant and sustained reduction in the concentration of DHT in both the plasma and androgen-sensitive tissues, which constitutes the central physiological consequence of the mechanism.


Mechanistic Constraints and Physiological Consequence

The resulting physiological change is the systemic reduction of the hormonal stimulus achieved by lowering the effective concentration of DHT. However, the mechanism is constrained by the drug's low affinity for the Type I 5alpha-Reductase isoform, meaning total DHT production is lowered but remains measurable. This physiological ceiling reflects the inherent constraint of the enzyme selectivity.

Dosage and Administration Information

Official Administration Guidelines for Lopecia (Finasteride 1 mg)

Lopecia (finasteride 1 mg) is prescribed for oral administration in adult men only and is not indicated for women or children. The instructions below describe the established protocol for use, strictly based on official labeling.

Dosage and Scheduling

Administration Scope Official Instruction
Route Oral (by mouth)
Dose One tablet (1 mg)
Frequency Once daily
Timing May be taken with or without meals

Procedural Steps

  1. Swallow one whole tablet with a drink of water. The tablet is film-coated and must not be crushed, broken, or chewed.
  2. Take the dose once daily, ideally at the same time each day to maintain consistency.
  3. Do not double the dose if a dose is missed. Skip the missed dose and resume the regular schedule with the next planned tablet. An extra dose will not make the medication work faster or better.
  4. Continued daily use for three months or more is generally required before a benefit is observed. Treatment must be maintained to sustain the effect, as stopping use leads to a reversal of the effect within 12 months.

Special Precautions for Handling

Women who are or may potentially be pregnant must not handle crushed or broken Lopecia tablets, as the medication can be absorbed and pose a risk to a male fetus. Whole tablets are coated to prevent contact with the active ingredient during normal handling.

Recent Clinical Evidence

Lopecia: Recent Clinical Evidence

Clinical research has explored the association between Lopecia, a Janus kinase (JAK) inhibitor, and outcomes in patients with chronic inflammatory conditions, particularly alopecia areata (AA). Trials have focused on whether the drug may modulate the inflammatory process that contributes to hair loss.

Core Efficacy Research

Randomized Controlled Trials (RCTs) evaluated the drug in adults and adolescents (aged 12 and older) with moderate-to-severe AA, often defined as 50% or greater scalp hair loss, comparing outcomes against a placebo over a period of 24 weeks.

Outcome Measured Finding Reported Severity Endpoint Time
SALT Score Change Significant reduction compared to placebo was observed. Moderate-to-Severe AA 12 and 24 Weeks
PGIC Score Patients reported significantly higher rates of overall improvement. Moderate-to-Severe AA 24 Weeks

The Severity of Alopecia Tool (SALT) score measures the percentage of scalp hair loss, where a reduction in score is associated with hair regrowth. The Patient Global Impression of Change (PGIC) reflects the patient's assessment of symptom improvement.

Combination and Long-Term Data

Studies investigated whether using Lopecia alongside other standard therapies was associated with a sustained reduction in disease activity over periods up to 52 weeks. Longer-term data were evaluated in extension studies. Research has reported that the profile of adverse events was generally minor and manageable. Further investigation is ongoing to characterize the full long-term profile and to identify patients who may derive the most benefit from this class of treatment.

Frequently Asked Questions (FAQ)

Common questions about Lopecia (FAQ)


Q: Do I need to take Lopecia forever?

A: According to official product information, continuous daily treatment must be maintained to sustain the intended effect. Regulatory documents state that if the medication is stopped, the effect achieved will typically reverse within 12 months. This describes why continuous use is required to maintain the benefit.


Q: Is it normal to feel a change in the first few weeks of taking Lopecia?

A: Clinical studies indicate that a patient benefit has generally been observed after three months or more of continuous daily use. However, some common adverse reactions, such as decreased interest in sex or difficulty achieving an erection, may be reported earlier in the course of treatment. If changes cause concern, official guidance directs patients to consult a healthcare provider.


Q: Is there any food or drink that officially interacts with Lopecia?

A: Regulatory documents state that food does not affect the body’s absorption of the drug. Specific interactions between this medication and alcohol are not listed in the official product labeling. Patients with specific concerns about consuming liquids with the medication are generally advised to consult a healthcare professional.


Q: How long after starting Lopecia is the full effect usually seen?

A: A therapeutic benefit has generally been observed in clinical studies after three months of continuous daily use. Regulatory information suggests that continued use is necessary, and the full effect typically increases and becomes more established over the first year of treatment.


Q: Are the side effects from Lopecia temporary?

A: Official documentation reports that side effects are often temporary. However, post-marketing data noted by multiple regulatory authorities indicate that sexual dysfunction, including decreased interest in sex and difficulty achieving an erection, may persist in some individuals after discontinuing treatment.


Q: Do any official documents classify Lopecia as having a high risk of side effects?

A: Official labeling includes statements on safety constraints. These warnings address the potential for psychiatric and sexual side effects, such as depression and suicidal thoughts, and a required caution about the increased risk of high-grade prostate cancer when using this class of drug.


Q: Does Lopecia interact with common pain relievers like ibuprofen?

A: Official studies found no clinically meaningful interactions with several compounds tested. Although specific interaction studies were not performed with every pain reliever, regulatory documents note that the drug was observed to be used concomitantly with analgesics, or pain relievers, in clinical studies.


Q: Is it okay to take multivitamins while using Lopecia?

A: Official interaction studies were not performed with every type of vitamin or supplement. However, regulatory documents state that the drug does not appear to affect the body's primary drug-metabolizing enzyme system (P450), which is interpreted to suggest a low potential for general metabolic interaction.


Q: Is Lopecia approved by the FDA (or similar agencies)?

A: Yes, the active ingredient in Lopecia (Finasteride 1 mg) is approved by major governmental regulatory agencies globally for its stated indication. These include the U.S. Food and Drug Administration (FDA) and other equivalent international bodies.


Q: Is Lopecia a hormonal drug?

A: Lopecia is classified as a 5-alpha reductase inhibitor, not a hormone itself. Its mechanism works by modulating the androgen metabolism pathway to reduce the concentration of the hormone Dihydrotestosterone (DHT) in the body, which results in an antiandrogenic effect.


Q: Can Lopecia affect blood pressure?

A: Official studies included co-administration of the drug with commonly used blood pressure medications, such as calcium-channel blockers and ACE inhibitors. Regulatory documents reported that no drug interactions of clinical importance were identified in these studies.


Q: What is the official 'half-life' of Lopecia?

A: The mean terminal half-life of the drug in plasma is approximately 5 to 6 hours in men aged 18 to 60 years. For men over 70 years of age, the half-life is approximately 8 hours, based on official studies.


Q: Can Lopecia interact with common antidepressants?

A: Official studies found no clinically meaningful interactions with several compounds tested. While specific interaction studies were not performed with all antidepressants, the drug was used concomitantly with benzodiazepines in clinical studies without clinically meaningful interactions being reported.


Q: What is the difference between the brand name and generic versions of Lopecia?

A: The active ingredient in Lopecia is Finasteride. Regulatory authorities classify brand name products and generic products as having the same active ingredient and dosage form.


Q: Does the efficacy of Lopecia vary based on age or gender?

A: The drug is only indicated for use in adult men and is contraindicated for use in women and children. Regulatory documents state that no dosage adjustment is considered necessary for older adult men.


Q: What should I do if I experience an uncommon side effect while on Lopecia?

A: Official guidance states that patients should be monitored for psychiatric and sexual side effects. Patients are instructed to contact a healthcare provider immediately if they develop concerning symptoms such as depression or suicidal thoughts.


Q: Do official prescribing documents list tiredness as a potential side effect?

A: Tiredness (fatigue) is not listed among the common, uncommon, or known-frequency adverse reactions in the official clinical trial and post-marketing sections of the labeling for the 1 mg dose.


Q: What are the official recommendations for checking up while on Lopecia?

A: Lopecia is known to reduce serum Prostate-Specific Antigen (PSA) levels by approximately 50%. This change must be accounted for by the healthcare provider when interpreting PSA test results for prostate cancer screening. This is a key requirement described in official documentation regarding monitoring while on the drug.


Q: Does Lopecia require routine blood work?

A: Due to the drug’s known effect on Prostate-Specific Antigen (PSA) levels, monitoring this marker is necessary for prostate cancer screening while on the drug. This specific check may require a blood test ordered by a healthcare provider.


Q: Does Lopecia come in different strengths or forms?

A: For its stated purpose (hair loss), the medication is available as a 1 mg film-coated oral tablet. It is noted that a different strength, 5 mg, is available for the treatment of other conditions, such as an enlarged prostate (BPH), but this is not the form indicated for this purpose.

How should Lopecia be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Lopecia (Minoxidil) are defined by regulatory labeling to maintain product stability and safety.

Storage Conditions:

  • Temperature: Store at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F).
  • Prohibited Environments: Do not freeze the medicine. Keep the product away from excessive heat, high humidity, and direct flame or fire due to potential flammability risks.
  • Packaging: Must be kept in the original container, which should be tightly closed.
  • Child Safety: It is mandatory to keep Lopecia out of the reach of children.

Disposal:

  • Do not use medicine that is outdated or expired.
  • The preferred disposal method is through an authorized Drug Take-Back Program or collection site.
  • Do not flush the medication down the toilet or pour it down a drain unless specifically instructed by governmental guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lopecia found in:

A-Z Index: